Clinical Trial

Dosage and Treatment of Advanced Solid Tumors

Study Description

A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

The purpose of this study is to investigate BMS-986226 administered alone or in combination with nivolumab or ipilimumab.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - BMS-986226

specified dose on specified days

Biological - Nivolumab

specified dose on specified days

Biological - Ipilimumab

specified dose on specified days

Biological - Tetanus Vaccine

specified dose on specified days

Additional Information

Official Study Title

A Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

Clinical Trial ID

NCT03251924

ParticipAid ID

Xe0zXb